Influence of pharmacokinetic profiles on safety and efficacy of hypnotic medications

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 13, 2006, Pages 9-12

  Erman, Milton K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; HYPNOTIC AGENT; QUAZEPAM; RAMELTEON; SEDATIVE AGENT; TEMAZEPAM; TRIAZOLAM; ZALEPLON; ZOLPIDEM;

DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG RELEASE; HALF LIFE TIME; HUMAN; INSOMNIA; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT;

EID: 33845353031     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Dorland's Illustrated Medical Dictionary. 29th ed. Philadelphia, Pa: WB Saunders Co; 2000
2. Dalmane (flurazepam). Physicians' Desk Reference. 60th ed. Montvale, NJ: Thomson PDR; 2006:3343-3344
3. Landolt H-P, Gillin JC. GABA receptors: involvement in sleep regulation and potential of selective agonists in the treatment of insomnia. CNS Drugs 2000;13:185-199
4. ProSom (estazolam). Physicians' Desk Reference. 60th ed. Montvale, NJ: Thomson PDR; 2006:512-515
5. Restoril [prescribing information]. St. Louis, Mo: Mallinckrodt Inc; 2004. Available at: http://www.restoril.com/pdf/restoril_prod_pi.pdf. Accessed June 13, 2006
6. Halcion [prescribing information]. Kalamazoo, Mich: Pharmacia & Upjohn Company; 2003. Available at: http://www.pfizer.com/pfizer/download/ uspi_halcion.pdf. Accessed June 13, 2006
7. National Institutes of Health. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. June 13-15, 2005, Available at: http://consensus.nih.gov/2005/2005InsomniaSOS026PDF. pdf. Accessed August 22, 2006
8. Walsh JK, Vogel GW, Scharf M, et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 2000;1:41-49
9. Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-199
10. Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005;6:487-495
11. Sonata [prescribing information]. Philadelphia. Pa: Wyeth Pharmaceuticals; 2006. Available at: http://www.kingpharm.com/uploads/ pdf_inserts/Sonata_Web_PI.pdf. Accessed June 13, 2006
12. Ambien [prescribing information]. New York. NY: Sanofi-Synthelabo; 2004. Available at: http://products.sanofi-aventis.us/ambien/ambien.html. Accessed June 13, 2006
13. Ambien CR [prescribing information]. New York, NY: Sanofi-Synthelabo; 2005. Available at: http://products.sanofi-aventis.us/ambien_cr/ambienCR.html. Accessed June 13, 2006
14. Weinling E, McDougal S, Andre F, et al. Pharmacokinetic profile of a new modified release formulation designed to improve sleep maintenance. Fundam Clin Pharmacol 2006;20:397-403
15. Lunesta [prescribing information]. Marlborough, Mass: Sepracor, Inc; 2005. Available at: http://www.lunesta.com/PostedApprovedLabeling Text.pdf. Accessed June 13, 2006
16. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-799
17. Rozerem [prescribing information]. Lincolnshire. Ill: Takeda Pharmaceuticals America; 2005. Available at: http://www.rozerem.com/images/pi. pdf. Accessed June 13, 2006